IL13 and neoplasm: IL13-PE (0.5 mg/mL, 0.75 mL/h over 96 hours) was administered via 2–4 intraparenchymal catheters placed in areas at greatest risk for infiltrating disease or in the vicinity of any residual, solid, contrast-enhancing disease 2–7 days after tumor resection.